Limited Edition Golden Llama is here! Check out how you can get one. Limited Edition Golden Llama is here! Check out how you can get one.
Happy Holiday! Limited Keychain here with your next orderHappy Holiday! Limited Keychain here with your next order
Time Limited Offer: Welcome Gift for New Customers ! Shipping Price Reduction for EU Regions
Kat. Nr. | Arten | Produktbeschreibung | Struktur | Reinheit | Merkmal |
---|---|---|---|---|---|
CD6-H5254 | Human | Human CD46 Protein, Fc Tag (MALS verified) |
|
||
CD6-H5226 | Human | Human CD46 Protein, His Tag (MALS verified) |
|
Immobilized Human CD46, His Tag (Cat. No. CD6-H5226) at 1 μg/mL (100 μL/well) can bind FG-3246 (FOR46), Human IgG1 kappa with a linear range of 0.3-2 ng/mL (QC tested).
The purity of Human CD46 Protein, Fc Tag (Cat. No. CD6-H5254) is more than 90% and the molecular weight of this protein is around 85-105 kDa verified by SEC-MALS.
Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
FOR-46 | FOR-46; FG-3246 | Phase 2 Clinical | University Of California San Diego, Fortis Therapeutics Inc | Prostatic Neoplasms, Castration-Resistant; Multiple Myeloma; Prostatic Neoplasms | Details |
Enadenotucirev | ColoAd-1; Oncolytic Ad11/Ad3 | Phase 1 Clinical | Akamis Bio Ltd | Ovarian Neoplasms; Rectal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Colonic Neoplasms; Neoplasms, Glandular and Epithelial; Urinary Bladder Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
YS-5 | YS-5 | Phase 1 Clinical | Fortis Therapeutics Inc, United States Department Of Defense | Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms | Details |
FOR-46 | FOR-46; FG-3246 | Phase 2 Clinical | University Of California San Diego, Fortis Therapeutics Inc | Prostatic Neoplasms, Castration-Resistant; Multiple Myeloma; Prostatic Neoplasms | Details |
Enadenotucirev | ColoAd-1; Oncolytic Ad11/Ad3 | Phase 1 Clinical | Akamis Bio Ltd | Ovarian Neoplasms; Rectal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Colonic Neoplasms; Neoplasms, Glandular and Epithelial; Urinary Bladder Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
YS-5 | YS-5 | Phase 1 Clinical | Fortis Therapeutics Inc, United States Department Of Defense | Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms | Details |
This web search service is supported by Google Inc.